Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 259

Posts Tagged ‘Oncology’

Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting

Posted by fidest press agency su sabato, 18 maggio 2019

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that four abstracts featuring data for Rubraca® (rucaparib) and ongoing studies in multiple tumor types will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4 in Chicago.The accepted abstracts summarize clinical trials in which Rubraca is being evaluated as a single agent and as combination therapy with nivolumab in a variety of solid tumor types including ovarian, prostate, biliary tract and endometrial cancers. These include additional genomic profiling data from TRITON2, and new data from extended follow up of patients in ARIEL3.“Increased understanding about the role of genomic mutations, as well as the growing number and type of oncology therapies, offer tremendous potential for us to more precisely target and improve treatment of the most challenging cancers,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “In our own clinical development program and in investigator-led studies, we are evaluating the utility of Rubraca in multiple solid tumor types where there is genomic rationale, including among patients with BRCA1/2 mutations as well as mutations in other genes that play a role in DNA repair.”
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, with additional office locations in the U.S. and Europe. Please visit for more information.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

American Oncology Network, LLC Appoints Inaugural Advisory Group

Posted by fidest press agency su lunedì, 8 aprile 2019

American Oncology Network, LLC Appoints Inaugural Advisory GroupWith a mission to support long-term viability of community oncology, the American Oncology Network, LLC (AON) has created a new advisory group to provide high-level strategic guidance to its practices and physicians.Consisting of AON physicians, executive management and administrative specialists, the group will advise on a range of trends impacting clinical and practice activities. The group’s goal is to serve as an advocate for AON’s physicians and physician groups, providing counsel and support on all issues related to business improvement, strategic development, quality and compliance.“It is a pleasure for us to introduce the AON Advisory Group to our practices, who will benefit from its recommendations,” said AON CEO Brad Prechtl. “The group will provide another layer of support to enhance practice services.”Inaugural group members include physicians from across the nation, such as Dr. Patrick Elwood and Dr. Taral Patel from the Zangmeister Cancer Center in Ohio; Dr. Michael Castine III from the Hematology/Oncology Clinic in Louisiana; Dr. Stephen “Fred” Divers from the Genesis Cancer Center in Arkansas; and Dr. Rangappa Rajendra from Oncology/Hematology of Loudoun and Reston in Virginia.
The AON Advisory Group’s executive management team members include AON CEO Brad Prechtl, COO Todd Schonherz, Regional Senior Vice President Steven Swart, Chief Revenue Cycle Officer Sarah Cevallos, Chief Information Officer Mark Moch, AON Board member and Strategic Advisor Dr. William Harwin, and AON Board Member Dr. Stephen Orman.AON is an alliance of physicians and seasoned health care leaders partnering to ensure the long-term success of community oncology. With more than three decades of expertise in all areas of oncology practice management, AON enables physicians to focus on what matters most — providing the highest-quality care for patients.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

American Oncology Network, LLC (AON) Introduces Specialty Oral Oncolytic Pharmacy

Posted by fidest press agency su martedì, 26 marzo 2019

The American Oncology Network, LLC (AON), an alliance of physicians and seasoned healthcare leaders, provides a unique array of support services to its affiliated community-based oncology practices, including in-house specialty pharmacy services. The AON Pharmacy streamlines the process of filling prescriptions for cancer patients who are being treated with oral oncolytic medications. According to the Community Oncology Alliance (COA), approximately 25% to 35% of all cancer drugs are currently available in pill form and that percentage is increasing each year.AON CEO Brad Prechtl, MBA, said, “Through the American Oncology Network, community oncology practices across the nation now have access to practice-proven solutions that bring tremendous value and benefit to their patients. The AON Pharmacy is a prime example of this. Pharmacy staff members not only handle the complicated insurance authorization process, they also work with patients and educate them about potential side effects of these powerful cancer drugs and ensure that patients are compliant and understand how to take prescribed medications.”Director of Pharmacy Ray Bailey added, “Our pharmacists are experts in oncology medications and they are available to speak with both patients and physicians, as needed. Through our electronic medical record (EMR), AON pharmacists can view a patient’s chart and then work directly with the patient’s oncologist to best manage any side effects of the oral therapies.”AON Board Member Dr. William Harwin pointed out, “When someone is diagnosed with cancer, he or she doesn’t want to wait several weeks to receive prescribed medications; yet, many of the smaller community oncology practices in the AON network don’t have the infrastructure to provide speedy access to oral oncology drugs. Through the AON Pharmacy, which ships directly to patients’ homes, usually within 48 to 72 hours, patients have easier, more convenient and much faster access to the medications they need.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

ALX Oncology to Present Preclinical Data on SIRPα Antibody Program at Upcoming Conferences

Posted by fidest press agency su domenica, 3 marzo 2019

ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that preclinical data for its SIRPα antibody research program will be presented at the 2019 Keystone Symposia Conference (Keystone), Cancer Immunotherapy in Whistler, British Columbia and the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia.CD47/SIRPα interaction is a key checkpoint mechanism exploited by cancer cells to escape immunological surveillance. While CD47 is widely expressed in human cells, SIRPα, the CD47 inhibitory receptor, is mainly expressed in myeloid cells and neurons. ALX148, a CD47 blocker with an inactive Fc domain, is generally well tolerated and demonstrates anti-cancer activity in combination with trastuzumab and pembrolizumab in patients with anti-HER2 and checkpoint inhibitor resistant/refractory disease (SITC 2018, P335). Another approach to block this interaction is to target SIRPα.“Targeting the CD47/SIRPα pathway is an exciting new approach that shows promise in clinical trials. By targeting SIRPα, we can investigate the similarities and differences of an orthogonal strategy to inhibit this axis,” said Hong Wan, Ph.D., ALX Oncology’s Chief Scientific Officer. “Our panel of proprietary high affinity monoclonal antibodies provides diverse epitope coverage across the extracellular surface of SIRPα. These antibodies are cross-reactive to human, monkey and rodent SIRPα variants, which enables robust clinical translation. Importantly, these antibodies bind to all human SIRPα variants, a critical attribute for a global patient population.” ALX Oncology’s SIRPα antibodies enhance the antitumor activity of immune checkpoint inhibitors, with reduction of metastases, eradication of tumors, and acquisition of memory immune response in tumor-bearing mice with intact immune systems. The cellular immune response in syngeneic models shows that these SIRPα antibodies enhance innate and adaptive anti-cancer immunity, providing a rationale for combination with other immunotherapies. In an exploratory toxicology study in monkeys, the selected SIRPα antibodies demonstrate a favorable pharmacokinetic, target occupancy and tolerability profile.Together, these preclinical data provide a compelling rationale to advance the development of anti-SIRPα therapy for patients with cancer.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Illumina Launches TruSight Oncology 500 to Power Comprehensive, Accurate, Pan-Cancer Tumor Profiling

Posted by fidest press agency su giovedì, 1 novembre 2018

Illumina, Inc. (NASDAQ: ILMN) today announces the launch of TruSightTM Oncology 500 (TSO 500), a comprehensive pan-cancer assay designed to identify known and emerging tumor biomarkers. TruSight Oncology 500 utilizes both DNA and RNA from subject tumor samples to identify key somatic variants underlying tumor progression, such as small DNA variants, fusions, and splice variants. Importantly, TruSight Oncology 500 can measure tumor mutational burden (TMB) and microsatellite instability (MSI), features that are potentially key biomarkers for emerging immunotherapies. TruSight Oncology 500 is for research use only and will ship in Q1 2019.Molecular testing in lung cancer has been at the forefront of precision oncology. The use of targeted therapies is associated with improved outcomes in some patients, and currently requires testing multiple biomarkers, such as EGFR mutations, ALK fusions, and ROS fusions, among others. Recently, TMB gained prominence as a biomarker that demonstrates better response and survival from immune checkpoint inhibitors in patients exhibiting high TMB, necessitating the need for comprehensive sequencing. Reliable measurement of TMB in a tumor-only workflow requires sequencing of approximately 1Mb or greater, specific and sensitive variant calling, as well as bioinformatic methods to flag and remove germline variants. Given the increasing number of biomarkers required to fully understand the optimal therapeutic course, assays like TruSight Oncology 500—one of the largest and most comprehensive panels to-date—encompasses all of these biomarkers, making it an ideal choice for cancer researchers today.“The importance of tumor mutational burden as a biomarker to predict immune checkpoint inhibition response continues to grow in non-small cell lung cancer,” said Albrecht Stenzinger, MD, pathologist at University Hospital Heidelberg, Germany. “However, the detection of somatic biomarkers, such as ALK fusions and EGFR small variants, are also vital. The workflow of TSO 500, using both DNA and RNA, enables laboratories to evaluate TMB, as well as small DNA variants and fusions simultaneously, ultimately saving time and preserving precious samples.” Pharmaceutical partners and payers are shifting toward deeper, broader sequencing to help predict which patients may benefit from new treatments including immunotherapies, targeted therapies and the many potential combinations. Recently, Bristol-Myers Squibb Company (NYSE: BMY) and Illumina announced a collaboration to develop and globally commercialize companion diagnostics, based on TruSight Oncology 500 content, to support Bristol-Myers Squibb’s oncology portfolio.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

AVEO Oncology to Participate in Upcoming Conferences

Posted by fidest press agency su mercoledì, 26 settembre 2018

AVEO Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company’s strategy is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. The Company is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced renal cell carcinoma (“RCC”). The Company has outlicensed tivozanib (FOTIVDA®) for oncology in Europe and other territories outside of North America. Tivozanib is approved in the European Union, as well as Norway and Iceland, for the first-line treatment of adult patients with RCC and for adult patients who are vascular endothelial growth factor receptor and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for RCC. The Company has entered into partnerships to fund the development and commercialization of AV-203 (CAN017) and ficlatuzumab, both clinical stage assets in oncology. The Company is currently seeking a partner to develop the AV-353 platform, a preclinical asset, worldwide for the potential treatment of pulmonary arterial hypertension. The Company has recently regained the rights to its AV-380 program for the potential treatment of cachexia and is considering a variety of options to advance the program’s development.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Integral Molecular’s MPS Antibody Discovery Platform Yields Therapeutic Assets for Oncology and Metabolic Syndrome

Posted by fidest press agency su sabato, 2 giugno 2018

Integral Molecular, the industry leader in membrane protein antibody discovery, announces the development of antibody assets targeting membrane proteins important in oncology (Claudin 6) and metabolic syndrome (GLUT4 and CB1). These therapeutic assets are among the first released in a pipeline of antibodies being isolated with the MPS Discovery Engine®, which is tailored for the discovery of rare, functional antibodies against complex membrane protein targets.In a paper published in PNAS (Tucker et al., May 2018), the company revealed the discovery of the first functional MAbs against GLUT4, an insulin-responsive glucose transporter important in diabetes. Epitope mapping showed that MAbs LM043 and LM048 are rare state-specific MAbs, selectively binding only certain active forms of the GLUT4 transporter.Last month at the PEGS protein engineering conference, Integral Molecular presented their discovery of antagonist MAb IM-102 against CB1 for NASH (inflammatory liver disease). IM-102 inhibits CB1 with 23 times greater potency than a benchmark MAb currently in phase 1 clinical trials. At the AACR conference this spring, the company presented its discovery of highly specific antibodies against Claudin 6, an established membrane protein target in ovarian cancer.
Ross Chambers, VP of Antibody Discovery, attributes the company’s 95% success rate in MAb isolation to optimization of its antibody discovery platform: “Our proprietary technologies allow us to obtain hundreds of diverse, high-affinity antibodies against complex targets, enabling us to discover antibodies with rare functional properties.”Integral Molecular’s MPS Discovery Engine® encompasses a technology suite that overcomes the obstacles of working with highly homologous and structurally complex targets. This suite includes antigen engineering and presentation on Lipoparticles, immunization of divergent species, and use of B-cell cloning to recover rare antibodies. Integral Molecular is currently isolating MAbs against dozens of membrane protein targets.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

UNC Cancer Care at Rockingham, a Service of UNC Hospitals, Adds Medical Oncology, Offering Comprehensive Cancer Care

Posted by fidest press agency su sabato, 12 maggio 2018

UNC Health Care announces the opening of UNC Cancer Care at Rockingham, a service of UNC Hospitals, on May 15. The newly named and expanded clinic will offer comprehensive cancer care and support services close to home for patients and their families.The clinic, previously known as the Smith McMichael Cancer Center, will now offer Medical Oncology and infusion services, in addition to the Radiation Oncology services that began earlier this year. Medical oncologist Dr. Bennett Winston Yu will work closely with patients starting May 15. Dr. Thomas C. Shea, a professor with the UNC School of Medicine and medical co-director of the UNC Bone Marrow Transplant and Cellular Therapy Program, will support Dr. Yu. They join Dr. Mohit Kasibhatla, a UNC Radiation Oncologist who began providing care on April 1.“When this hospital joined UNC Health Care last year, one of our top goals was to expand the care and services available in our community,” said Dana Weston, president of UNC Rockingham. “Unfortunately, cancer strikes far too often in this region. We are proud to offer much-needed and comprehensive cancer care and support that’s convenient for our patients and their families.” Patients receiving care at UNC Cancer Care at Rockingham will be able to readily access the expertise of UNC Cancer Care’s providers, a site close to home for infusion therapy, and will receive high-quality, compassionate and state-of-the-art treatment for a wide range of cancers. Surgical services, offered at UNC Rockingham Hospital, is another compliment to the care available.UNC Rockingham Health Care, formerly known as Morehead Memorial Hospital, became part of UNC Health Care and unveiled its new name on Jan.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

MUSC Health and Alliance Oncology Expand Cancer Care in Beaufort, S.C.

Posted by fidest press agency su mercoledì, 7 febbraio 2018

san frnciscoSan Francisco. Alliance Oncology and the Medical University of South Carolina Health System (MUSC Health) announced today that they will partner with Beaufort Memorial Hospital to relocate and expand the hospital’s radiation oncology center to its main campus in late 2018. This project represents Alliance Oncology’s vision to be a driver in transforming healthcare by partnering with leading providers to expand regional services to communities – thus giving patients and their providers improved access, convenience and services closer to home. “In partnership with MUSC Health and Beaufort Memorial Hospital we are excited to add this location benefitting the local Beaufort community, and to augment academic cancer care services in the region,” said Greg Spurlock, President of Alliance Oncology. “As one of the nation’s leading providers of cancer care, this center will join Alliance affiliated locations across the country in providing high-quality, patient-centered services in partnership with premier cancer care providers and caregivers.” At the new Beaufort Memorial Keyserling Cancer Center, an MUSC clinical advisory committee will collaborate closely with local oncology experts and a dedicated clinical liaison will be onsite in the radiation oncology center. This expands upon the collaboration that was formed in 2016 when Beaufort Memorial Keyserling Cancer Center began enrolling qualifying cancer patients in clinical trials through an affiliation with the National Cancer Institute-designated Hollings Cancer Center at MUSC. “Given the needs of our patients throughout the state, it is imperative that we find innovative affiliations such as this one to ensure we are reaching all of those who need the expertise of our teams,” said Patrick J. Cawley, M.D., CEO, MUSC Health and Vice President for Health Affairs at Medical University of South Carolina. “We are excited and pleased to work with our colleagues at Alliance Oncology and Beaufort Memorial to bring the expertise of the Hollings Cancer Center even closer to those who need us.” “Beaufort Memorial Hospital has been providing outstanding cancer care to the community for more than a decade,” says Russell Baxley, MHA, President and CEO of Beaufort Memorial Hospital. “Our new and expanded partnership with MUSC and Alliance Oncology allows us to offer cutting-edge technology and resources locally, providing the latest in cancer care to our patients.”Alliance Oncology partners directly with hospitals and physicians to develop fully integrated oncology programs. Providing a full range of inpatient and outpatient service line capabilities, Alliance Oncology’s comprehensive approach to cancer care affords its partners the speed-to-market, quality clinical outcomes, patient satisfaction and operational expertise that sets them apart from the competition. (foto: san francisco)

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

GE, Roche Enter Partnership to Develop Integrated Digital Diagnostics Platform to Improve Oncology and Critical Care Treatment

Posted by fidest press agency su martedì, 9 gennaio 2018

Roche Enter PartnershipGE Healthcare has entered into a strategic, long-term partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.The two companies aim to develop an industry-first digital platform, using advanced analytics to provide workflow solutions and apps that support clinical decisions. This will allow the seamless integration and analysis of in-vivo and in-vitro data, patient records, medical best practice, real time monitoring and the latest research outcomes. Clinicians will then have the comprehensive decision support for providing the right treatment and quality of care for their patients.For example, oncology care teams with multiple specialists will have a comprehensive data dashboard to review, collaborate and align on treatment decisions for cancer patients at each stage of their disease. In the critical care setting, data from a patient’s hospital monitoring equipment will be integrated with their biomarker, tissue pathology, genomic and sequencing data, helping physicians to identify, or even predict severe complications before they strike.GE Healthcare is a worldwide leader in medical imaging equipment, while Roche Diagnostics is the global leader in in-vitro diagnostics.“This is the first time that two major players in healthcare have combined advanced analytics with in-vivo and in-vitro diagnostics to this degree. We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients and the healthcare industry,” said Kieran Murphy, President & CEO of GE Healthcare.“This unique partnership will deliver innovative solutions and insights in clinical decision-making. Our goal is to support clinicians and other relevant stakeholders for the benefit of patients by providing the right decision support at the right time and through comprehensive digital offerings,” said Roland Diggelmann, CEO Roche Diagnostics.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Spectrum Pharmaceuticals Announces Leadership Changes

Posted by fidest press agency su martedì, 19 dicembre 2017

Natali a New York (2)New York. Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its Board of Directors has terminated Rajesh C. Shrotriya, MD without cause from his position as Chief Executive Officer, and announced leadership changes under which Joseph W. Turgeon, the current President and Chief Operating Officer, has been named President and Chief Executive Officer and elected to the Board of Directors, and current Director Stuart M. Krassner, ScD, PsyD, has been named Chairman of the Board. In addition, Thomas J. Riga, who currently serves as Executive Vice President, Chief Commercial Officer and Head of Business Development, has been named Chief Operating Officer. These changes are effective immediately.Mr. Turgeon brings more than 30 years of experience in the pharmaceutical industry, including various executive leadership roles at Amgen Inc. He had served as Spectrum’s President and Chief Operating Officer since April 2014, and had previously served as the Company’s Senior Vice President and Chief Commercial Officer from October 2012 to April 2014. Prior to joining Spectrum, Mr. Turgeon spent 22 years at Amgen Inc. as Vice President of Sales.
Mr. Riga brings over 15 years of pharmaceutical sales and management experience in various positions at Amgen, Eli Lilly and Dendreon, including as Vice President of Sales at Dendreon. He had served as Spectrum’s Executive Vice President, Chief Commercial Officer and Head of Business Development since June 2017, and previously served as Spectrum’s Senior Vice President and Chief Commercial Officer from August 2014 to June 2017, and Vice President, Corporate Accounts from July 2013 to August 2014.
Dr. Krassner has served as a director of Spectrum since December 2004, and was previously a member of Spectrum’s Scientific Advisory Board from 1996 to 2001. Dr. Krassner’s career spans nearly four decades of experience in positions of increasing responsibility at the University of California at Irvine, most recently as Professor of Developmental and Cell Biology at the School of Biological Sciences. Dr. Krassner is Professor Emeritus, University of California, Irvine and has also been retained by pharmaceutical, medical device and other companies, including Allergan Pharmaceuticals, Lasermed Corporation, Automated Microbiology Systems, and In Vitro International, among others, to provide scientific and regulatory advisory services, including FDA compliance. He is a past member of the American Academy for the Advancement of Sciences, and the American Society of Tropical Medicine and Hygiene, among others.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

BTG and SIO Expand Immuno-Oncology

Posted by fidest press agency su giovedì, 24 agosto 2017

londonLONDON/PRNewswire/BTG plc (LSE: BTG), a global specialist healthcare company, and the Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, have expanded their commitment to the Immuno-Oncology / Interventional Oncology research grant programme, by announcing a second round of funding available to investigators.Interventional oncology, which includes a range of minimally invasive, image guided, loco-regional therapies, and immuno-oncology, using the body’s own immune system to treat cancer, are two areas of scientific interest that have great potential for improving cancer therapy. The SIO grant programme is designed to fund cutting-edge research initiatives to investigate the potential for these therapeutic approaches to work in combination. Specifically, the programme is looking to fund research proposals that:
Evaluate immune stimulation of interventional oncologic therapies
Combination approaches to improve clinical outcome
Improve the understanding of underlying mechanisms as to how different loco-regional therapies influence both adaptive and innate immunity
Earlier this year, four investigators were awarded grants at the World Conference on Interventional Oncology (WCIO) in Boston to further their cutting-edge research in the field. Their project proposals ranged from exploratory pilot projects to prospective clinical trials. The winners were chosen by the SIO Immuno-Oncology / Interventional Oncology Committee, a panel of international experts which includes both interventional radiologists and immuno-oncologists.With a large number of high quality submissions and the level of interest in the programme to date, BTG and SIO have announced their intention to expand the programme to ensure more collaborative research will be funded and accelerate the pace of scientific advancement in the combination of interventional oncology and immuno-oncology therapies.”We are very pleased with the ongoing generosity of BTG that will continue to enable the SIO to fund additional meritorious, cutting-edge research that combines the strengths of interventional oncology and immuno-oncology – two disciplines that hold great promise for improving cancer therapy,” said S. Nahum Goldberg, MD, SIO Interventional / Immuno-oncology Working Group Chair, and Vice-Chair for Research and Head of the Interventional Oncology Unit, Hadassah Hebrew University Medical Center in Jerusalem, Israel.Melanie Lee, Chief Scientific Officer of BTG, said: “We were delighted by the number of high calibre entries we saw from investigators in response to the original call for proposals, with lots of brilliant ideas of how to best combine loco-regional and immunotherapies. We believe such approaches can help new agents to penetrate solid tumour mass, expose tumour specific antigens, and help the immune system to mount a response. Given the high levels of interest, we have decided to double our efforts and provide further funding in 2018 to support additional research in this area.”
To apply for a grant, completed applications need to be submitted online at by the 15th December 2017. The submission must include a detailed research plan that outlines a one to two year budget proposal and a letter of support from the department chair (for faculty applicants) or fellowship director (for trainee applicants). Grants of up to $50,000 are available for one year exploratory pilot projects and up to $100,000 for larger one to two year projects.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

A Copenaghen il Congresso della European Society for Medical Oncology

Posted by fidest press agency su domenica, 9 ottobre 2016

copenaghen. Copenaghen. L’Italia spende meno per i farmaci anti-cancro rispetto a Germania e Francia ma ottiene guarigioni superiori in neoplasie frequenti come quelle del seno, del colon-retto e della prostata. In particolare, nel nostro Paese nel 2014 le uscite per queste terapie hanno raggiunto i 2 miliardi e 900 milioni, in Germania 6,2 e in Francia 4,2 miliardi. Il tema della sostenibilità dei nuovi trattamenti è al centro dell’agenda del 41° Congresso della Società europea di Oncologia Medica (European Society for Medical Oncology, ESMO) in corso a Copenaghen. “Finora il nostro sistema sanitario ha retto garantendo l’accesso alle cure a tutti i pazienti, grazie anche ai sistemi di rimborso concordati con l’Agenzia Italiana del Farmaco (AIFA) – spiega il prof. Carmine Pinto, presidente nazionale AIOM (Associazione Italiana di Oncologia Medica) -. L’intensità dell’innovazione farmaceutica preannuncia l’ingresso sul mercato di molti farmaci salvavita. Siamo di fronte a una rivoluzione epocale che richiede di essere affrontata con visione e decisione. Siamo consapevoli dei vincoli di finanza pubblica, ma questa rivoluzione terapeutica può essere affrontata solo immettendo risorse dedicate. Per questo lanciamo un forte messaggio e chiediamo un incontro al Presidente del Consiglio Matteo Renzi, da sempre attento al tema dell’innovazione – come dimostra il progetto Human Technopole – e alla salvaguardia dell’universalismo del nostro sistema sanitario nazionale, per sviluppare per la prima volta in Italia un Progetto unitario e strategico contro i tumori. Un ‘Patto contro il cancro’, un’alleanza tra Oncologi, Governo e Istituzioni, capace di mobilitare risorse e di dare una risposta concreta alle richieste di 3 milioni di pazienti oncologici italiani, sul modello di programmi già lanciati negli Stati Uniti. Un ‘Patto’ capace di valorizzare l’Oncologia italiana, tra le eccellenze del nostro Paese, e di offrire un significato nuovo all’azione politica in sanità pubblica. L’AIOM è partita da proposte strutturali a lungo termine e nel breve periodo con una proposta concreta: l’istituzione di un ‘Fondo nazionale per l’Oncologia’. La nostra proposta sul Fondo si inserisce quindi in un progetto più ampio, decisivo per milioni di cittadini, il ‘Patto contro il cancro’”. Nel tumore del seno la sopravvivenza a cinque anni in Italia è dell’86,2% (85,3% in Germania, 83,7% in Spagna, 81,1% in UK), nel polmone del 14,7% (13,6% in Francia, 12,6% in Spagna, 9,6% in UK), nello stomaco del 32,4% (31,6% in Germania, 27,7% in Francia, 27,3% in Spagna, 18,5% in UK), nel colon del 63,2% (59,8% in Francia, 59,3% in Spagna, 53,8% in UK), e nella prostata del 89,7% (91,2% in Germania, 90,5% in Francia, 87,1% in Spagna, 83,2% in UK). A livello globale oltre 20 tipi di tumore sono stati trattati con più di 70 nuove molecole lanciate negli ultimi cinque anni, portando così il costo mondiale per i farmaci anticancro a 107 miliardi di dollari nel 2015 con un incremento dell’11,5% rispetto al 2014 (era pari a circa 90 miliardi nel 2011). “Guardando alle prospettive future, secondo stime accreditate – continua il prof. Pinto –, nel 2016 il settore farmaceutico registrerà in Italia uno sforamento del tetto programmato, che sarà difficile ripianare anche ricorrendo agli strumenti oggi in uso”. I costi del trattamento sono aumentati in modo esponenziale: quello giornaliero medio di un farmaco antineoplastico in Italia è passato da 42,20 euro nel periodo 1995-1999 a 203,47 euro nel 2010-2014. Il costo medio di una terapia complessiva è aumentato da 3.853 euro nel 1995-1999 a 44.900 euro nel 2010-2014. “L’incremento – sottolinea il prof. Pinto – va ricondotto anche al fatto che molti nuovi farmaci prevedono la somministrazione fino a progressione di malattia invece che un numero finito di cicli come accadeva con la ‘classica’ chemioterapia. Inoltre nel Continente vi sono gravi disparità in materia di organizzazione sanitaria, oggi acuite dalla forte crisi economica. In particolare queste diseguaglianze interessano i Paesi dell’Est. È necessario un intervento legislativo a livello europeo perché non è più sostenibile la frammentazione tra i singoli Stati membri di diverse valutazioni del costo-beneficio dei farmaci: ciò determina ulteriori differenze, causando variazioni sostanziali nel costo dello stesso trattamento oncologico da un Paese all’altro”. In Italia nel 2016 sono stimate più di 365mila diagnosi di cancro, nell’Unione Europea i nuovi casi registrati sono stati 2.635.222 (anno 2012). A partire dal 2011 si è assistito a una riduzione dei tassi di mortalità globale nella UE (8% tra i maschi e 3% tra le donne) e nel 2016 sono previsti 1.359.500 decessi. “Le proiezioni per il 2016 – conclude il prof. Pinto – confermano il deciso declino di mortalità a livello europeo per il cancro del polmone nei maschi e il suo aumento nelle donne. Un andamento simile si registra anche in Italia con un decremento della mortalità negli uomini del 2,6% annuo dal 1999 al 2016 rispetto a un aumento del 2% fra le femmine, dovuto al preoccupante aumento del vizio del fumo nelle donne”.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Geriatric oncology

Posted by fidest press agency su sabato, 6 dicembre 2014

tumoreUn tumore su due colpisce uomini e donne durante la terza età. Ma le sperimentazioni dei farmaci oncologici sono nel 99% dei casi svolte su persone con meno di 65 anni. “Dobbiamo cambiare le linee guida internazionali sulle malattie tumorali e riadattare terapie e cure al loro vero paziente target: l’anziano”. E’ questo l’appello lanciato oggi dagli oltre 300 specialisti riuniti nella Capitale per il 1ST Rome International Meeting in Geriatric Oncology. “Oncologo e geriatra devono spesso lavorare su un “terreno fragile” – afferma il prof. Guido Francini, Direttore dell’Oncologia Medica dell’Università di Siena e presidente del convegno internazionale che si concluderà domani -. Un anziano, a differenza di un paziente giovane, soffre di tutta una serie di malattie come ipertensione, diabete, insufficienza renale o scompenso cardiaco. Per essere efficaci le terapie devono tener conto del “fattore età” e di tutte le problematiche che può avere una persona con più di 65 anni. Inoltre l’organismo, durante la vecchiaia, non riesce a tollerare determinate tossicità di alcuni farmaci oncologici”. Il 1st Rome International Meeting on Geriatric Oncology è organizzato dall’Università di Siena e di Roma Sapienza. Gode del patrocinio, tra gli altri, dell’Associazione Italiana di Oncologia Medica (AIOM), dell’American Society of Clinical Oncology (ASCO) e dell’adesione del Presidente della Repubblica. “Lo scopo principale dell’incontro internazionale è approfondire le nostre conoscenze sulla malattia oncologica nell’anziano – prosegue Francini -. Il congresso vuole sensibilizzare il personale medico e sanitario a un nuovo approccio clinico. Dobbiamo creare percorsi assistenziali specifici per i pazienti oncologici over 65. Per cercare di raggiungere questi ambiziosi obiettivi ci siamo avvalsi di un team composto dai più grandi esperti internazionali e nazionali in oncogeriatria”. Negli anziani, il rischio di ammalarsi di tumore è 40 volte più alto rispetto alle persone di 20-40 anni e 4 volte maggiore rispetto a quelle di 45-65 anni. “Secondo le ultime previsioni demografiche, nel 2030 circa il 30% degli italiani avrà più di 65 anni – ricorda Francini -. In futuro dobbiamo aspettarci un aumento significativo del numero di neoplasie e di anziani colpiti. Contro il cancro sarà dunque necessaria una sempre più forte collaborazione tra oncologi e geriatri. Ma anche la prevenzione potrà avere un ruolo fondamentale. Il 40% dei tumori è evitabile seguendo stili di vita sani. Per evitare gravi problemi di salute durante la terza età è necessario fin da giovani non fumare, limitare il consumo di alcol, seguire una dieta sana ed equilibrata, svolgere regolarmente attività fisica e sottoporsi ad esami medici”.

Posted in Cronaca/News, Medicina/Medicine/Health/Science, Roma/about Rome | Contrassegnato da tag: , , , | Leave a Comment »

Tumori: nasce la carta europea

Posted by fidest press agency su sabato, 14 dicembre 2013

Annals of Oncology

Annals of Oncology (Photo credit: Wikipedia)

Il prof. Stefano Cascinu, presidente AIOM: “La nostra specialità deve rimanere autonoma. Questo documento ci difende contro i tentativi di impoverirla riconducendola nell’ambito della medicina interna. Il periodo di formazione non può essere ridotto a quattro anni”
Milano, 13 dicembre 2013 – Un documento per garantire l’autonomia dell’oncologia medica in ogni Paese europeo e assicurare le cure migliori a tutti i pazienti. Nasce la Carta stilata dalle società scientifiche del Vecchio Continente riunite nell’ESMO (European Society for Medical Oncology), con l’Associazione Italiana di Oncologia Medica (AIOM) in prima linea, che definisce, in modo chiaro e formale, chi è l’oncologo medico. Oggi il cancro fa meno paura, infatti quasi il 60% delle persone colpite dalla malattia guarisce, ma l’autonomia della disciplina non può essere messa in discussione. “Negli ultimi mesi – afferma il prof. Stefano Cascinu, Presidente AIOM – abbiamo assistito con preoccupazione al rischio di vedere la nostra specialità ridotta a quattro anni, contravvenendo alla Direttiva Europea che fissa invece in un quinquennio il periodo di formazione. Il pericolo per ora sembra scongiurato, ma questo documento può ulteriormente proteggerci da tentativi di impoverimento dei percorsi formativi dei nostri specializzandi. E non è sostenibile l’idea di ricondurre l’oncologia all’interno della medicina interna. Va riconosciuto il carattere multidisciplinare della nostra specialità”. Il carico di lavoro dei camici bianchi, come evidenziato dalla V Edizione del Libro Bianco AIOM, è in costante crescita: in ogni struttura di oncologia medica del nostro Paese si eseguono in media 6170 visite ambulatoriali all’anno (erano 3.000 nel 1999, 3.400 nel 2004 e 5.000 nel 2008): i ricoveri sono 730 con una durata di circa 5 giorni. Ogni reparto ha una disponibilità di 15 posti letto e vi lavorano 6 medici strutturati. I risvolti del position paper, pubblicato oggi su Annals of Oncology, sono numerosi e importanti. “Il primo – spiega la dott.ssa Marina Garassino, Rappresentante italiana dell’ESMO – è difendere la qualità di cura per i nostri pazienti indipendentemente dalle barriere geografiche”. Nel 2013 si stimano in Italia 366.000 nuove diagnosi di cancro (erano 364mila nel 2012): 200.000 (55%) negli uomini e 166.000 (45%) nelle donne.
L’evoluzione della cura dei tumori richiede una figura specialistica sempre più preparata alle costanti evoluzioni e cambiamenti in materia, sia nell’ambito della diagnosi che delle terapie. “Solo la preparazione professionale dell’oncologo medico – sottolinea il prof. Razvan Popescu, coordinatore ESMO dei Rappresentanti nazionali europei e primo autore dell’articolo – al momento attuale è in grado di fornire garanzie nel trattamento e nella cura di questi pazienti”.
L’oncologia è una specialità relativamente recente, nata negli anni Sessanta, ma solo nel marzo 2011 è stata formalmente riconosciuta come specialità indipendente dall’Unione Europea. “Definire con chiarezza chi è l’oncologo medico – continua il dott. Massimo di Maio del Direttivo nazionale AIOM – abbatte le barriere anche per cercare lavoro all’estero. E garantisce il riconoscimento della nostra professionalità in qualsiasi Paese”. “Sono particolarmente a favore di questo documento – afferma il prof. Fortunato Ciardiello, presidente eletto ESMO -, il cancro è oggi una patologia a forte impatto economico e sociale ed è perciò necessario difendere l’autonomia della disciplina oncologica in tutta Europa”. “La cura dei pazienti oncologici – conclude la prof.ssa Martine Piccart, Presidente ESMO – è sempre più complessa e andrebbe perseguita in un ambito ‘olistico’ multidisciplinare, in cui l’oncologo ha un ruolo centrale nel team multidisciplinare insieme ad altre figure, come il chirurgo e il radioterapista”.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Interventional Oncology – Combinational Technologies Play a Crucial Role for the European Outlook

Posted by fidest press agency su venerdì, 12 luglio 2013

LONDON A decade ago, there was little interest in interventional cancer therapies. Five years ago, newly diagnosed cases of different types of cancer stood at about 12.7 million with 7.6 million related deaths registered. According to the WHO GLOBOCAN database, the top three diagnosed cancer forms in 2008 included lung – 1.61 million, breast – 1.38 million, and colorectal – 1.23 million, while the most common types of cancer with leading death rate were lung – 1.38 million, stomach – 0.74 million, and liver – 0.69 million. These alarming statistics have made interventional oncology a rapidly evolving speciality. Traditional surgical techniques are now increasingly being replaced by minimally invasive imaging-guided procedures. Primary interventional techniques include thermal ablation, high intensity focused ultrasound (HIFU), and embolization. Radiofrequency ablation (RFA) and cryoablation are already considered sound treatment options, while transarterial chemoembolization (TACE) is probably the worldwide standard for treatment of unresectable hepatocellular carcinoma, with drug-eluting beads being the first major technology advancement in TACE. Microwave ablation (MWA), irreversible electroporation, and HIFU are evolving interventional technologies.
“The popularity of interventional technology is increasing; looking into the future, the medical fraternity is considering it as a major treatment possibility,” said Frost & Sullivan Healthcare Senior Analyst Akanksha Joshi. “Cost effectiveness and improvement in quality of life are the main merits achieved with interventional oncology.” Although surgery remains the standard treatment method for most forms of cancer, there is ample space for new technologies to be implemented. MWA has introduced advantages over RFA and is steadily growing in sales. Selective internal radiation therapy (SIRT) and HIFU too are gaining ground due to clear benefits like targeted therapy and non-invasiveness, respectively. “Presented as the most accurate and patient-friendly procedures that are applicable to a wide patient base, TACE, HIFU and SIRT are in the growth phases and likely to gain a much larger market share in the future,” noted Joshi. “Unfortunately, treatment methods using ablation technologies and SIRT have little or no reimbursement in Europe despite the clear demand for minimally invasive and non-invasive methods that increase patient comfort, reduce patient hospital stay, and hence decrease treatment costs for both hospitals and patients. Surgery continues to be the trusted and globally reimbursed mode of treatment for cancer.” Further, full clinical evidence for the effective use of new technologies is still lacking. Most studies are vendor sponsored which means parameters to evaluate the device vary and results may thus not be unbiased. Increasing investment in research will improve existing devices and technologies’ output. For instance, tissue overheating during MWA may be avoided by implementing power control algorithms, and advanced ergonomic devices are being designed with instinctive controls and features. Manufacturers will greatly benefit from the fact that many interventional oncology technologies can be used as combinational technology. Numerous possibilities have been researched, such as heat activated liposomal doxorubicin with RFA. Similarly, both HIFU and RFA help in the deposition of doxorubicin. Studies also indicate that the combination of technologies such as RFA with TACE, or percutaneous ethanol injection (PEI) with RFA or TACE provides better-quality treatment. Clinical trials are currently being performed to prove the efficacy of such combined technologies. “Availability of reimbursement for interventional oncology technologies would make them more popular as combinational technologies,” stressed Joshi. “This trend would favour the use of different techniques as per necessity and benefit of patients.” Going forward, image-guided multimodality routing, computerisation and visualisation, along with electromagnetic radiation, drug delivery and immunotherapy, are expected to play a pivotal role in curing cancerous tissues. Methods gaining popularity in this treatment space include image-guided stereotactic radiotherapy with modern methods of respiratory synchronization. For now, combinational technology will offer medical oncologists a choice of additional treatment, although there still remains a need to search for a technology that can substitute surgery. Collaboration between the science and medical communities, and manufacturers will pave the way for an effective treatment solution.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | 1 Comment »